• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Volato Announces Changes to Board Composition

    4/24/24 6:00:00 AM ET
    $BSX
    $SOAR
    $NVCN
    Medical/Dental Instruments
    Health Care
    Transportation Services
    Consumer Discretionary
    Get the next $BSX alert in real time by email

    Volato to Announce First Quarter 2024 Results on Wednesday, May 15, 2024

    Volato Group, Inc. ("Volato," or the "Company") (NYSE:SOAR) today announced that it has appointed Christopher G. Burger and Fred A. Colen to the Company's Board of Directors. As part of this announcement, Joan Sullivan Garrett, Katherine Arris-Wilson, Peter Mirabello, and Dana H. Born have stepped down from the Company's Board of Directors without disagreement.

    The company is decreasing the size of its board from seven to five members, three of whom are Independent Directors. Fred Colen will serve as an independent director and Chair of the Audit Committee and has been designated as a financial expert. Chris Burger will serve as an independent director and Chair of the Nominating and Corporate Governance Committee. Michael Nichols has served as an independent director since August of 2021 and has been elected as Lead Independent Director; Mr. Nichols will continue to serve as Chair of the Compensation Committee. Matthew Liotta, Chief Executive Officer and Co-Founder of Volato, has been elected Chairman of the Board of Directors. Nicholas Cooper, Chief Commercial Officer and co-founder, will continue to serve as a director.

    Mr. Liotta commented, "I'd like to thank each of the departing directors for their service to Volato. We are very pleased to introduce Chris Burger and Fred Colen to our upgraded board structure, bringing with them an exceptional mix of expertise in technology and aviation. This strategic enhancement of our board will sharpen our decision-making and accelerate our financial goals. With their guidance and a more nimble board structure, we are poised to drive Volato forward, reinforcing our commitment to innovation in the private aviation industry."

    Christopher G. Burger Bio

    Chris Burger is a proven senior executive, C-level advisor, and Board member with extensive experience leading global organizations through critical business and technology transformation initiatives. Chris has direct international management experience spanning five continents and currently serves as President & CEO of Transform with a mission to help clients and team members achieve their greatest potential and fulfillment. Notable Transform Aviation clients include, among others, Delta Air Lines, FedEx, United Airlines, and USAF Air Mobility Command. Earlier in his career, Chris held roles of increasing responsibility at GE and Motorola across digitization, acquisition integration, program and project management, strategic programs, global business planning and competitive intelligence. Chris holds a Bachelor of Business Administration degree with a Marketing Distinction Certificate from Emory University's Roberto C. Goizueta Business School.

    Fred A. Colen Bio

    Mr. Colen is an experienced public company executive and director. He has served as Chairman of the Board of Xeltis AG, an international medical device company, since 2023. Since 2017, Mr. Colen has served on the Board of Directors of Onward Medical (Euronext: ONWD). From January 2018 to April 2023, he served as the President and Chief Executive Officer of Neovasc Inc. (NASDAQ:NVCN). Prior to joining Neovasc Inc., Mr. Colen served as the President and Chief Executive Officer at BeneChill, Inc., a medical device company in San Diego, California, from 2011 to 2016. Before joining BeneChill, Inc., Mr. Colen served in various capacities at Boston Scientific (NYSE:BSX) from 1999 to 2010. Mr. Colen holds a Master of Electrical Engineering with a specialization in Biomedical Engineering from the University of Aachen in Germany. Mr. Colen is qualified to serve on the Board because of his significant public company board and managerial experience.

    The departing board members' resignations are not related to any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.

    Earnings Conference Call

    Volato will release its financial results for the first quarter ended March 31, 2024, before market open on Wednesday, May 15, 2024. and will host a conference call to discuss the results at 8:00am ET on the same day.

    Interested parties can access the conference call by dialing 866-605-1830 for toll free access or +1 215-268-9881. The live call will also be available via webcast on Volato's Investor Relations website: https://ir.flyvolato.com/.

    A replay of the call will be available until August 14, 2024 and can be accessed by dialing 877-660-6853 or 201-612-7415 and using the Access ID: 13746297.

    Cautionary Note on Forward Looking Statements

    This press release contains certain "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of the control of Volato that could cause actual results to differ materially from the results discussed in the forward-looking statements. The words "anticipate," "believe," continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "strive," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward-looking. These forward-looking statements are subject to a number of risks, uncertainties and assumptions that could cause actual events and results to differ materially from those contained in such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements can be found in the Annual Report on Form 10-K, filed with the SEC on March 26, 2024 and other documents filed by the Company from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and Volato undertakes no obligation and does not intend to update or revise these forward-looking statements, whether because of new information, future events, or otherwise.

    About Volato

    Volato (NYSE:SOAR) is a leader in private aviation, redefining air travel through modern, efficient, and customer-designed solutions. Volato provides a fresh approach to fractional ownership, aircraft management, jet card, deposit and charter programs, all powered by advanced, proprietary mission control technology. Volato's fractional programs uniquely offer flexible hours and a revenue share for owners across the world's largest fleet of HondaJets, which are optimized for missions of up to four passengers. For more information visit www.flyvolato.com.

    All Volato Part 135 charter flights are operated by its DOT/FAA-authorized air carrier subsidiary (G C Aviation, Inc. d/b/a Volato) or by an approved vendor air carrier.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240423912104/en/

    Get the next $BSX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BSX
    $SOAR
    $NVCN

    CompanyDatePrice TargetRatingAnalyst
    Boston Scientific Corporation
    $BSX
    10/3/2025Buy → Hold
    Erste Group
    Boston Scientific Corporation
    $BSX
    9/8/2025$125.00Perform → Outperform
    Oppenheimer
    Boston Scientific Corporation
    $BSX
    6/16/2025$118.00Outperform
    Leerink Partners
    Boston Scientific Corporation
    $BSX
    4/16/2025$113.00Hold → Buy
    Needham
    Boston Scientific Corporation
    $BSX
    1/10/2025$108.00Hold → Buy
    Deutsche Bank
    Boston Scientific Corporation
    $BSX
    10/18/2024Buy → Hold
    Needham
    Boston Scientific Corporation
    $BSX
    5/30/2024$90.00Buy
    Goldman
    Boston Scientific Corporation
    $BSX
    2/1/2024$65.00 → $80.00Neutral → Buy
    Mizuho
    More analyst ratings

    $BSX
    $SOAR
    $NVCN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 1, 2024 - FDA Roundup: March 1, 2024

    For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

    3/1/24 4:00:21 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $SOAR
    $NVCN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    ALAMEDA, Calif., Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2025. Financial Highlights:Revenue of $385.4 million for the fourth quarter of 2025, an increase of 22.1% or 20.9% in constant currency1, compared to the fourth quarter of 2024.Revenue of $1,403.7 million for the full year 2025, an increase of 17.5% or 16.9% in constant currency1, compared to the full year 2024.U.S. Thrombectomy revenue of $203.1 million for the fourth quarter

    2/25/26 1:00:00 PM ET
    $BSX
    $PEN
    Medical/Dental Instruments
    Health Care

    Boston Scientific elects Cathy Smith and Christophe Weber to Board of Directors

    MARLBOROUGH, Mass., Feb. 23, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) announced today the election of Cathy Smith and Christophe Weber to its Board of Directors, effective February 18, 2026. Smith is a seasoned executive with deep expertise in finance, corporate strategy and operational excellence. She currently serves as chief financial officer of Starbucks. Previously, she held chief financial officer roles at Nordstrom, Bright Health, Target, Express Scripts and Walmart, supporting large, complex organizations through periods of significant growth. Smith

    2/23/26 8:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    M2i Global, along with Volato Group, and SMX Execute Collaboration Agreement for Pilot Initiative to Enable Secure Tracking and Traceable Critical Minerals Commerce Through CAINO and the M2i Metals Marketplace

    Agreement is first step to advance critical minerals shipment assurance, digital chain-of-custody, and authenticated marketplace transactions Atlanta, GA and Reno, NV, Feb. 19, 2026 (GLOBE NEWSWIRE) -- M2i Global, Inc. ("M2i," the "Company," "we," "our" or "us") (OTCQB:MTWO), a company specializing in the development and execution of a complete global value supply chain for critical minerals, along with Volato Group, Inc. ("Volato") (NYSE:SOAR), a technology-driven company, is pleased to announce that it has entered into a Strategic Collaboration Agreement with SMX (Security Matters) PLC (NASDAQ:SMX) ("SMX"), a publicly traded company focused on supply chain traceability and integrity sol

    2/19/26 9:00:00 AM ET
    $SMX
    $SOAR
    Industrial Machinery/Components
    Technology
    Transportation Services
    Consumer Discretionary

    $BSX
    $SOAR
    $NVCN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by EVP& Grp Pres, MedSurg & APAC Butcher Arthur C

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    2/27/26 5:31:09 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Weber Christophe Pierre

    3 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    2/24/26 4:13:36 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    New insider Smith Cathy R claimed ownership of 141 shares (SEC Form 3)

    3 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    2/24/26 4:12:34 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $SOAR
    $NVCN
    SEC Filings

    View All

    SEC Form S-4 filed by Boston Scientific Corporation

    S-4 - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    2/27/26 4:35:50 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    2/26/26 5:11:42 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    2/23/26 4:33:54 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $SOAR
    $NVCN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Boston Scientific downgraded by Erste Group

    Erste Group downgraded Boston Scientific from Buy to Hold

    10/3/25 8:32:04 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Boston Scientific from Perform to Outperform and set a new price target of $125.00

    9/8/25 8:36:41 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Leerink Partners initiated coverage on Boston Scientific with a new price target

    Leerink Partners initiated coverage of Boston Scientific with a rating of Outperform and set a new price target of $118.00

    6/16/25 7:46:14 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $SOAR
    $NVCN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Group Pres, Cardiology Fitzgerald Joseph Michael bought $4,515 worth of shares (50 units at $90.29), sold $1,799 worth of shares (20 units at $89.97), was granted 31,680 shares and covered exercise/tax liability with 14,447 shares, increasing direct ownership by 17% to 172,863 units (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    2/13/25 4:32:41 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Prachar Michael Patrick bought $988 worth of shares (1,235 units at $0.80) (SEC Form 4)

    4 - Volato Group, Inc. (0001853070) (Issuer)

    6/10/24 6:38:24 PM ET
    $SOAR
    Transportation Services
    Consumer Discretionary

    Chief Executive Officer Liotta Matthew bought $4,860 worth of shares (6,000 units at $0.81), increasing direct ownership by 0.13% to 4,797,271 units (SEC Form 4)

    4 - Volato Group, Inc. (0001853070) (Issuer)

    6/10/24 6:35:35 PM ET
    $SOAR
    Transportation Services
    Consumer Discretionary

    $BSX
    $SOAR
    $NVCN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Volato Group Inc.

    SC 13G/A - Volato Group, Inc. (0001853070) (Subject)

    11/14/24 7:58:49 AM ET
    $SOAR
    Transportation Services
    Consumer Discretionary

    SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

    SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)

    2/13/24 5:00:46 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

    SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)

    2/9/24 11:49:03 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $SOAR
    $NVCN
    Financials

    Live finance-specific insights

    View All

    Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    ALAMEDA, Calif., Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2025. Financial Highlights:Revenue of $385.4 million for the fourth quarter of 2025, an increase of 22.1% or 20.9% in constant currency1, compared to the fourth quarter of 2024.Revenue of $1,403.7 million for the full year 2025, an increase of 17.5% or 16.9% in constant currency1, compared to the full year 2024.U.S. Thrombectomy revenue of $203.1 million for the fourth quarter

    2/25/26 1:00:00 PM ET
    $BSX
    $PEN
    Medical/Dental Instruments
    Health Care

    Boston Scientific announces results for fourth quarter and full year 2025

    MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational1 basis and 12.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $672 million or $0.45 per share (EPS), compared to $566 million or $0.38 per share a year ago, and achieved adjusted3 EPS of $0.80 for the period, compared to $0.70 a year ago.

    2/4/26 6:30:00 AM ET
    $BSX
    $PEN
    Medical/Dental Instruments
    Health Care

    Boston Scientific announces agreement to acquire Penumbra, Inc.

    Acquisition to expand Boston Scientific's cardiovascular portfolio and further address increasing prevalence of vascular diseases Provides scaled entry into mechanical thrombectomy and neurovascular, key strategic adjacencies Conference call at 8:00 a.m. ET to discuss details of the transaction MARLBOROUGH, Mass. and ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) and Penumbra, Inc., (NYSE:PEN) today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock transaction that values Penumbra at $374 per share, reflecting an enterprise value of approximately $14.5 billion.i

    1/15/26 7:00:00 AM ET
    $BSX
    $PEN
    Medical/Dental Instruments
    Health Care

    $BSX
    $SOAR
    $NVCN
    Leadership Updates

    Live Leadership Updates

    View All

    M2i Global, along with Volato Group, and Titanium X Sign Strategic Collaboration Agreement to Advance Critical Mineral Development in the United States

    Includes Exclusive Supply Agreement of Titanium Concentrate Atlanta, GA and Reno, NV, Jan. 07, 2026 (GLOBE NEWSWIRE) -- M2i Global, Inc. ("M2i," the "Company," "we," "our" or "us") (OTCQB:MTWO), a company specializing in the development and execution of a complete global value supply chain for critical minerals, along with Volato Group, Inc. ("Volato") (NYSE:SOAR), a technology-driven company, is pleased to announce a strategic collaboration agreement with Titanium X, marking a major step forward in advancing domestic refining capabilities and securing the critical materials supply chain essential to U.S. industry and national security. Under the agreement, Titanium X and M2i Global will

    1/7/26 2:00:00 PM ET
    $SOAR
    Transportation Services
    Consumer Discretionary

    Volato Group Appoints Alan D. Gaines to Board of Directors

    Veteran Investment Banker and Energy Industry Leader to Serve as Audit Committee Chairman Volato Group, Inc. (the "Company" or "Volato") (NYSE:SOAR), today announced the appointment of Alan D. Gaines to its Board of Directors, effective immediately. Mr. Gaines will also serve as Chairman of the Audit Committee. Mr. Gaines is an accomplished investment banker, strategic advisor, and entrepreneur with more than four decades of experience in global capital markets, energy, critical minerals, and infrastructure development. Over his career, he has led or participated in more than 200 major transactions, raising over $100 billion in aggregate capital. He is the Executive Chairman, CEO, and

    12/29/25 8:30:00 AM ET
    $SOAR
    Transportation Services
    Consumer Discretionary

    CathVision Announces Appointment of Eric Thepaut as Independent Chairman of the Board and Releases ECGenius® System Version 3.5

    COPENHAGEN, Denmark, Dec. 10, 2025 /PRNewswire/ -- CathVision, a medical technology company dedicated to improving clinical outcomes in cardiac electrophysiology through high-fidelity signal acquisition and intelligent software, today announced two major milestones: the appointment of Eric Thepaut as independent Chairman of the Board, and the commercial release of Version 3.5 of the ECGenius® System. Eric Thepaut Appointed Independent Chairman of the Board Eric Thepaut joins CathVision following his recent retirement from Boston Scientific Corporation (NYSE:BSX), where he serv

    12/10/25 4:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care